MiRNA-29: A microRNA family with tumor-suppressing and immune-modulating properties

Current Molecular Medicine

Volumn 13, Issue 4, 2013, Pages 572-585

  Schmitt, M J ^a   Margue, C ^a   Behrmann, I ^a   Kreis, S ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

Biomarker; Immune response; MiR 29 family; Oncogenic; Therapeutic target; Tumor suppressor

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA BETA INTERFERON RECEPTOR; BETA1 INTEGRIN; BIOLOGICAL MARKER; COLLAGEN; CYCLIN DEPENDENT KINASE 6; DNA METHYLTRANSFERASE; ELASTIN; EOMESODERMIN; FIBRILLIN 1; GAMMA INTERFERON; LUCIFERASE; MICRORNA 29; PROTEIN P42; PUMA PROTEIN; SOMATOMEDIN C; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YY1;

B CELL LYMPHOMA; CANCER INHIBITION; DOWN REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; WESTERN BLOTTING;

GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNE SYSTEM; MICRORNAS; NEOPLASMS;

EID: 84876717265     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313040009     Document Type: Review

References (113)

1. Jovanovic M, Hengartner MO. Mirnas and apoptosis: RNAs to die for. Oncogene 2006; 25(46): 6176-6187.
2. Esau C, Kang X, Peralta E, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004; 279(50): 52361-52365.
3. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94(6): 776-780.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-269.
5. Chang TC, Mendell JT. MICRORNAS in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007; 8: 215-239.
6. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39(Database issue): D152-157.
7. Bartel DP. MICRORNAS: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-297.
8. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23(20): 4051-4060.
9. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6(5): 376-385.
10. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11(9): 597-610.
11. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294(5543): 853-858.
12. Villarreal G, Jr, Oh DJ, Kang MH, Rhee DJ. Coordinated regulation of extracellular matrix synthesis by the microrna-29 family in the trabecular meshwork. Invest Ophthalmol Vis Sci 2011; 52(6): 3391-3397.
13. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105(35): 13027-13032.
14. Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. MIR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 2010; 332(1-2): 125-133.
15. Ugalde AP, Ramsay AJ, de la Rosa J, et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J 2011; 30(11): 2219-2232.
16. Steiner DF, Thomas MF, Hu JK, et al. MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. Immunity 2011; 35(2): 169-181.
17. Ahluwalia JK, Khan SZ, Soni K, et al. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 2008; 5: 117.
18. Hand NJ, Horner AM, Master ZR, et al. MicroRNA Profiling Identifies miR-29 as a Regulator of Disease-associated Pathways in Experimental Biliary Atresia. J Pediatr Gastroenterol Nutr 2012; 54(2): 186-192.
19. Chen T, Li Z, Tu J, et al. MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Lett 2011; 585(4): 657-663.
20. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 Family: Genomics, Cell Biology, and Relevance to Renal and Cardiovascular Injury. Physiol Genomics 2012; 44(4): 237-244.
21. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009; 137(3): 586-591.
22. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40(1): 43-50.
23. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110(5): 1155-1164.
24. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 2007; 104(45): 17719-17724.
25. Saini HK, Enright AJ, Griffiths-Jones S. Annotation of mammalian primary microRNAs. BMC Genomics 2008; 9: 564.
26. Marson A, Levine SS, Cole MF, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008; 134(3): 521-533.
27. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 2009; 4(4): e5279.
28. Chien CH, Sun YM, Chang WC, et al. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. Nucleic Acids Res 2011; 39(21): 9345-9356.
29. Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13(6): 496-506.
30. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9(3): 189-198.
31. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353(17): 1793-1801.
32. Eyholzer M, Schmid S, Wilkens L, Mueller BU, Pabst T. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer 2010; 103(2): 275-284.
33. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6(13): 1586-1593.
34. Park SY, Lee JH, Ha M, Nam JW, Kim VN. MIR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16(1): 23-29.
35. Kapinas K, Kessler CB, Delany AM. MIR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. J Cell Biochem 2009; 108(1): 216-224.
36. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010; 10(12): 1224-1232.
37. Cortez MA, Nicoloso MS, Shimizu M, et al. MIR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 2010; 49(11): 981-990.
38. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67(13): 6130-5.
39. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103(10): 3687-3692.
40. Wang H, Garzon R, Sun H, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14(5): 369-381.
41. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51(3): 836-845.
42. Fang JH, Zhou HC, Zeng C, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011; 54(5): 1729-1740.
43. Muniyappa MK, Dowling P, Henry M, et al. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 2009; 45(17): 3104-3118.
44. Wang C, Bian Z, Wei D, Zhang JG. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 2011; 352(1-2): 197-207.
45. Gebeshuber CA, Zatloukal K, Martinez J. MIR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10(4): 400-405.
46. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010; 70(10): 4163-4173.
47. Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011; 6(3): 388-394.
48. Han YC, Park CY, Bhagat G, et al. MICRORNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010; 207(3): 475-489.
49. Wang F, Wang XS, Yang GH, et al. MIR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 2011; 39(3): 2713-2722.
50. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. MICRORNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113(21): 5237-5245.
51. Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114(18): 3872-3879.
52. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66(24): 11590-11593.
53. Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010; 107(27): 12210-12215.
54. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113(25): 6411-6418.
55. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104(40): 15805-15810.
56. Ulivi P, Zoli W, Calistri D, et al. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006; 206(3): 611-615.
57. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003; 9(12): 4415-4422.
58. Saito Y, Kanai Y, Nakagawa T, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003; 105(4): 527-532.
59. Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002; 33(3): 163-171.
60. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999; 59(10): 2302-2306.
61. Kim H, Kwon YM, Kim JS, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006; 107(5): 1042-1049.
62. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9(1): 47-59.
63. Kole AJ, Swahari V, Hammond SM, Deshmukh M. MIR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev 2011; 25(2): 125-130.
64. Mott JL, Kobayashi S, Bronk SF, Gores GJ. MIR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26(42): 6133-6140.
65. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010; 87(3): 535-544.
66. Sengupta S, den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105(15): 5874-5878.
67. Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010; 62(6): 1733-1743.
68. Liu Y, Taylor NE, Lu L, et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension. 2010; 55(4): 974-982.
69. Sengupta S, den Boon JA, Chen IH, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 2006; 66(16): 7999-8006.
70. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449(7164): 919-922.
71. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28(4): 477-487.
72. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75(2): 163-189.
73. Kohanbash G, Okada H. MicroRNAs and STAT interplay. Semin Cancer Biol 2012; 22(1): 70-75.
74. Reinsbach S, Nazarov PV, Philippidou D, et al. Dynamic regulation of microRNA expression following Interferon-gamma-induced gene transcription. RNA Biol 2012; 9(7): 978-989.
75. Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol 2010; 40(1): 225-231.
76. Papadopoulou AS, Dooley J, Linterman MA, et al. The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor. Nat Immunol 2012; 13(2): 181-187.
77. Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011; 12(9): 861-869.
78. Anastasiadou E, Boccellato F, Vincenti S, et al. Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. Oncogene 2010; 29(9): 1316-1328.
79. Hariharan M, Scaria V, Pillai B, Brahmachari SK. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 2005; 337(4): 1214-1218.
80. Kirchhoff F, Schindler M, Specht A, Arhel N, Munch J. Role of Nef in primate lentiviral immunopathogenesis. Cell Mol Life Sci 2008; 65(17): 2621-2636.
81. Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, Rana TM. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 2009; 34(6): 696-709.
82. Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 2008; 5: 118.
83. Sun G, Li H, Wu X, et al. Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res 2012; 40(5): 2181-2196.
84. Wang F, Wang XS, Yang GH, et al. MIR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 2012; 39(3): 2713-2722.
85. Zhao JJ, Lin J, Lwin T, et al. MICRORNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115(13): 2630-2639.
86. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2011; 36(1): e61-67.
87. Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, et al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol 2012; 40(6): 2097-2103.
88. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112(1): 55-59.
89. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001; 97(9): 2823-2829.
90. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97(5): 1172-1179.
91. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107(16): 7473-7478.
92. Poltronieri P, D'Urso PI, Mezzolla V, D'Urso OF. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem Biol Drug Des 2013; 81(1): 79-84.
93. Seth S, Johns R, Templin MV. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv 2012; 3(2): 245-261.
94. Osman A. MicroRNAs in health and disease--basic science and clinical applications. Clin Lab 2012; 58(5-6): 393-402.
95. Bail S, Swerdel M, Liu H, et al. Differential regulation of microRNA stability. RNA 2010; 16(5): 1032-1039.
96. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316(5824): 575-579.
97. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science 2007; 315(5808): 97-100.
98. Zhang Z, Zou J, Wang GK, et al. Uracils at nucleotide position 9-11 are required for the rapid turnover of miR-29 family. Nucleic Acids Res 2011; 39(10): 4387-4395.
99. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6(11): 836-848.
100. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331(6024): 1565-1570.
101. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7(1): 41-51.
102. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9(11): 798-809.
103. Smith KM, Guerau-de-Arellano M, Costinean S, et al. MIR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. J Immunol 2012; 189(4): 1567-1576.
104. Mizuarai S, Irie H, Kotani H. Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in biomarker-driven anti-tumor drug development. Curr Mol Med 2010; 10(6): 596-607.
105. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10(2): 142-165.
106. Rossbach M. Small non-coding RNAs as novel therapeutics. Curr Mol Med 2010; 10(4): 361-368.
107. Li Y, Wang F, Xu J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol 2011; 224(4): 484-495.
108. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011; 6(5): e19518.
109. Verrier JD, Lau P, Hudson L, Murashov AK, Renne R, Notterpek L. Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. Glia 2009; 57(12): 1265-1279.
110. Cui Y, Su WY, Xing J, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS One 2011; 6(10): e25872.
111. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69(3): 1135-1142.
112. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127(1): 118-126.
113. Schmitt MJ, Philippidou D, Reinsbach SE, et al. Interferon-Y-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal 2012; 10(1): 41.